NasdaqCM - Nasdaq Real Time Price USD

Lexaria Bioscience Corp. (LEXX)

1.6700

+0.0800

+(5.03%)

As of 3:50:22 PM EDT. Market Open.

LEXX: Second Quarter Results

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal second quarter 2025 results through the filing of its Form 10-Q. Since our previous update, the company has made progress with its multiple GLP-1 trials, received patent awards in epilepsy and shared its strategy for advancing its development candidates. Lexaria’s

Zacks Small Cap Research 10 hours ago

LEXXW
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) ...

ACCESS Newswire yesterday

LEXX
+5.03%
LEXXW
We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 19 days ago

LEXX
+5.03%
LEXXW
Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, ...

ACCESS Newswire 21 days ago

LEXX
+5.03%
LEXXW
Lexaria's Human GLP-1 Study #5 Begins Dosing

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) ...

ACCESS Newswire 22 days ago

LEXX
+5.03%
LEXXW
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound® As previously announced, oral DehydraTECH-tirzepatide also ...

ACCESS Newswire last month

LEXX
+5.03%
LEXXW
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" ...

ACCESS Newswire last month

LEXX
+5.03%
LEXXW
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

5th study arm in 12-week Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery ...

ACCESS Newswire last month

LEXX
+5.03%
LEXXW
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces ...

ACCESS Newswire 2 months ago

LEXX
+5.03%
LEXXW
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for ...

ACCESS Newswire 2 months ago

LEXX
+5.03%
LEXXW
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study ...

ACCESS Newswire 2 months ago

LEXX
+5.03%
LEXXW
Lexaria Releases Annual Letter from the CEO

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from its Chief Executive ...

ACCESS Newswire 2 months ago

LEXX
+5.03%
LEXXW
LEXX: IRB Approval Clears Way for GLP-1 Study #5

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase Ib trial evaluating DehydraTECH in obese patients. Several new patents were granted bringing the corporate total to 43.

Zacks Small Cap Research 2 months ago

LEXXW
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received the necessary independent ethics ...

ACCESS Newswire 3 months ago

LEXX
+5.03%
LEXXW
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic ...

ACCESS Newswire 3 months ago

LEXX
+5.03%
LEXXW
Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Lexaria Bioscience ( NASDAQ:LEXX ) First Quarter 2025 Results Key Financial Results Net loss: US$2.70m (loss widened by...

Simply Wall St. 3 months ago

LEXX
+5.03%
LEXXW
Lexaria's Registered GLP-1 Study #4 Begins Dosing

KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic ...

ACCESS Newswire 4 months ago

LEXX
+5.03%
LEXXW
Lexaria Forms New Scientific Advisory Board

Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the creation of its new Scientific Advisory Board ("SAB") to assist in guiding Lexaria's rapid drug delivery ...

ACCESS Newswire 4 months ago

LEXX
+5.03%
LEXXW
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly ...

ACCESS Newswire 4 months ago

LEXX
+5.03%
LEXXW
Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide

Lexaria Bioscience (LEXX) announced the engagement of a contract research organization to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda injectable liraglutide. As reported on November 20th in Lexaria’s 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide – administered orally – demonstrated a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline. The Rybelsus control, which was expected to outperf

TipRanks 4 months ago

LEXX
+5.03%
LEXXW

Performance Overview

Return	LEXX	S&P 500 (^GSPC)
YTD	-20.48%	-6.68%
1-Year	-24.09%	+8.23%
3-Year	-44.33%	+28.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lexaria Bioscience Corp. (LEXX)

LEXX: Second Quarter Results

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Releases Annual Letter from the CEO

LEXX: IRB Approval Clears Way for GLP-1 Study #5

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide

Performance Overview